Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Josh Kopelman
Deal Size : $7.0 million
Deal Type : Financing
Details : Eigen will use the capital to apply their novel high-throughput platform toward the development of priming therapies. Their initial programs are focused on hematological malignancies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Josh Kopelman
Deal Size : $7.0 million
Deal Type : Financing
Reset All
